Cargando…

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

OBJECTIVES: Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for quantitative determination of infliximab and to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Stappen, Thomas, Bollen, Lize, Vande Casteele, Niels, Papamichael, Konstantinos, Van Assche, Gert, Ferrante, Marc, Vermeire, Séverine, Gils, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288585/ https://www.ncbi.nlm.nih.gov/pubmed/27929524 http://dx.doi.org/10.1038/ctg.2016.62

Ejemplares similares

The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile
por: Bollen, Lize, et al.
Publicado: (2015)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

New treatment options for inflammatory bowel diseases
por: Verstockt, Bram, et al.
Publicado: (2018)

Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment
por: Arijs, Ingrid, et al.
Publicado: (2009)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Vaccination and infection prevention in inflammatory bowel disease
por: Vermeire, Severine, et al.
Publicado: (2010)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Papamichael, Konstantinos, et al.
Publicado: (2022)

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
por: Gils, Ann, et al.
Publicado: (2014)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells
por: Creyns, Brecht, et al.
Publicado: (2020)

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
por: Verstockt, Bram, et al.
Publicado: (2020)

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease
por: Verstockt, Bram, et al.
Publicado: (2018)

Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13
por: Creyns, Brecht, et al.
Publicado: (2019)

Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
por: Faelens, Ruben, et al.
Publicado: (2021)

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study
por: Westera, Liset, et al.
Publicado: (2017)

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022)

Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
por: Cleynen, Isabelle, et al.
Publicado: (2019)

Value of drug level testing and antibody assays in optimising biological therapy
por: Vermeire, Séverine, et al.
Publicado: (2013)

Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
por: Sabino, João, et al.
Publicado: (2016)

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease
por: Verdon, Christine, et al.
Publicado: (2020)

Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium
por: Creyns, Brecht, et al.
Publicado: (2020)

Metabolic Profiling of the Impact of Oligofructose-Enriched Inulin in Crohn's Disease Patients: A Double-Blinded Randomized Controlled Trial
por: De Preter, Vicky, et al.
Publicado: (2013)

Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease
por: de Bruyn, Magali, et al.
Publicado: (2017)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Preparing for a Second Attack: A Lesion Simulation Study on Network Resilience After Stroke
por: van Assche, Mitsouko, et al.
Publicado: (2022)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Integrated miRNA and mRNA Expression Profiling in Inflamed Colon of Patients with Ulcerative Colitis
por: Van der Goten, Jan, et al.
Publicado: (2014)

Suppression of pathergy in pyoderma gangrenosum with infliximab allowing for successful tendon debridement
por: Leiphart, Paul A., et al.
Publicado: (2017)

Assessment of the Microbiota in Microdissected Tissues of Crohn's Disease Patients
por: De Hertogh, Gert, et al.
Publicado: (2012)

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Distinct cardioprotective mechanisms of immediate, early and delayed ischaemic postconditioning
por: Barsukevich, Veronika, et al.
Publicado: (2014)

The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression
por: Li, Xiaoxue, et al.
Publicado: (2020)

Unique Gene Expression and MR T(2) Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn’s Disease
por: Breynaert, Christine, et al.
Publicado: (2013)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tecaiict5bnbmooosoa9gjkugf